Patent Notice
60px
spacer
large
In accordance with 35 U.S.C. § 287(a), the following table provides notice that the listed Lilly products are protected by patents in the United States and includes representative U.S. patent numbers associated with each product. The table is subject to change and may not include all patents associated with each product or all Lilly products that are protected by patents. Lilly owns or has exclusive licenses to additional U.S. and foreign patents that may be associated with the listed Lilly products or other Lilly products.
16px
spacer
large
Product
16px
Associated Patent(s)
16px
AMYVID® (florbetapir F 18) injection
16px
U.S. 7,687,052; U.S. 8,506,929
16px
CYRAMZA® (ramucirumab) injection
16px
U.S. 7,498,414; U.S. 10,766,961
16px
EBGLYSS® (lebrikizumab-lbkz) injection
16px
U.S. 8,067,199; U.S. 8,088,618; U.S. 9,067,994; U.S. 9,605,065; U.S. 10,000,562; U.S. 10,597,446; U.S. 10,597,447; U.S. 10,947,307; U.S. 11,434,286
16px
EMGALITY® (galcanezumab-gnlm) injection
16px
U.S. 9,073,991; U.S. 9,505,838; U.S. 11,498,959
16px
JAYPIRCA® (pirtobrutinib) tablets
16px
U.S. 10,342,780; U.S. 10,464,905; U.S. 10,695,323; U.S. 10,918,622; U.S. 12,109,193; U.S. 12,220,401; U.S. 12,268,666
16px
KISUNLA™ (donanemab-azbt) injection
16px
U.S. 8,679,498; U.S. 8,961,972; U.S. 11,312,763
16px
LYUMJEV® (insulin lispro-aabc) injection
16px
U.S. 9,439,952; U.S. 9,901,623; U.S. 9,993,555; U.S. 10,172,922; U.S. 10,925,931; U.S. 11,123,406
16px
MOUNJARO® (tirzepatide) injection
16px
U.S. 9,474,780; U.S. 11,357,820; U.S. 12,295,987; U.S. 12,343,382; U.S. 12,453,755; U.S. 12,453,756
16px
OLUMIANT® (baricitinib) tablets
16px
U.S. 8,158,616; U.S. 8,420,629; U.S. 9,089,574; U.S. 9,737,469; U.S. 11,045,474; U.S. 11,806,555
16px
OMVOH® (mirikizumab-mrkz) injection
16px
U.S. 9,023,358; U.S. 9,688,753; U.S. 12,152,072
16px
RETEVMO® (selpercatinib) tablets
16px
U.S. 10,112,942; U.S. 10,137,124; U.S. 10,172,851; U.S. 10,584,124; U.S. 10,786,489; U.S. 11,963,950; U.S. 12,138,250
16px
REYVOW® (lasmiditan) tablets
16px
U.S. 7,423,050; U.S. 11,053,214; U.S. 12,071,423; U.S. 12,257,246
16px
TALTZ® (ixekizumab) injection
16px
U.S. 7,838,638; U.S. 8,110,191; U.S. 11,634,485
16px
TAUVID™ (flortaucipir F 18) injection
16px
U.S. 8,932,557
16px
TRULICITY® (dulaglutide) injection
16px
U.S. 7,452,966; U.S. 8,273,854; U.S. 11,576,950; U.S. 11,890,325
16px
VERZENIO® (abemaciclib) tablets
16px
U.S. 7,855,211
16px
ZEPBOUND® (tirzepatide) injection
16px
U.S. 9,474,780; U.S. 11,357,820; U.S. 11,918,623; U.S. 12,343,382; U.S. 12,453,756; U.S. 12,453,758
16px